论文部分内容阅读
目的探讨替吉奥(S-1)联合奥沙利铂(L-OHP)治疗晚期胃癌的临床疗效及安全性。方法 64例进展期胃癌患者分为两组,替吉奥联合奥沙利铂组(治疗组)34例,替吉奥每天80mg/m2,早晚各服1次,连服14d;奥沙利铂130mg/m2第1天,静脉滴注2h,3周为1个周期。卡培他滨联合奥沙利铂组(对照组)30例,同时口服希罗达每次1000mg/m2,每天2次,第1～14天;奥沙利铂130mg/m2第1天,静脉滴注2h,每3周为1个周期。4个周期后评价疗效及毒性。结果 64例患者均可评价疗效,治疗组和对照组的有效率分别为55.9%和53.3%,疾病控制率分别为79.4%和73.3%,两组差异均无统计学意义(P>0.05)。两组不良反应主要为血液学毒性、恶心呕吐、腹泻、外周神经毒性等,以I～II度为主,患者均可耐受。结论替吉奥联合奥沙利铂方案治疗晚期胃癌疗效好,且不良反应可耐受。
Objective To investigate the clinical efficacy and safety of tioguanoside (S-1) and oxaliplatin (L-OHP) in the treatment of advanced gastric cancer. Methods Sixty-four patients with advanced gastric cancer were divided into two groups: TEGA combined with oxaliplatin group (treatment group), 34 cases, TIGO 80mg / m2 daily, morning and evening one time, even for 14 days; oxaliplatin 130mg / m2 on the first day, intravenous infusion 2h, 3 weeks for a cycle. Capecitabine and oxaliplatin group (control group) 30 cases, while oral Xeloda 1000mg / m2, 2 times a day, 1 to 14 days; Oxaliplatin 130mg / m2 on the 1st day, the vein Instillation 2h, 1 cycle every 3 weeks. After 4 cycles evaluation of efficacy and toxicity. Results The curative effect was evaluated in 64 patients. The effective rates of treatment group and control group were 55.9% and 53.3% respectively, and the disease control rates were 79.4% and 73.3% respectively. There was no significant difference between the two groups (P> 0.05). Two groups of adverse reactions are mainly hematological toxicity, nausea and vomiting, diarrhea, peripheral neurotoxicity, etc., to I ~ II degrees, the patient can be tolerated. Conclusion The treatment of advanced gastric cancer with the combination of tioguanide and oxaliplatin is effective and tolerable.